Moderna, Inc. Reports $1.5 Billion Credit Facility
Summary
On November 19, 2025, Moderna, Inc. entered into a Credit and Guaranty Agreement with lenders and Ares Capital Corporation, establishing a $1.5 billion credit facility (via Ex. 10). This facility includes an initial $600 million term loan and $900 million in delayed draw term loans, with the latter contingent on achieving key regulatory milestones aligned with the Company's late-stage clinical pipeline. The loans mature on November 24, 2030, and are guaranteed by certain subsidiaries and secured by an all-asset collateral grant.
Why It Matters
This $1.5 billion credit facility provides significant financing for Moderna, Inc., including funds contingent on late-stage clinical pipeline milestones, which could support future growth and operations.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Key Quote
“The Credit Agreement provides for a $1,500,000,000 credit facility of which $600,000,000 will be funded as an initial term loan and $900,000,000 will be available as delayed draw term loans.”
— From Item 1.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Monday, November 24, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive